Supplementation, optimal status, and analytical determination of vitamin D: Where are we standing in 2012?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 36-44

  Souberbielle, Jean Claude ^a   Cavalier, Etienne ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

25 hydroxyvitamin D; Calcitriol; Immunoassay; Mass spectrometry; Parathyroid hormone; Reference values; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; KETOCONAZOLE; PARATHYROID HORMONE; PREDNISONE; VITAMIN D; VITAMIN D RECEPTOR;

CHRONIC KIDNEY DISEASE; HUMAN; NONHUMAN; OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 84880162612     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152013804487317     Document Type: Review

References (81)

1. Holick, M.F.; Chen, T.C.; Lu, Z.; Sauter, E. J. Vitamin and skin physiology: a delightful story. Bone Miner. Res., 2007, 2(suppl 2): V28-V33.
2. Schlingmann, K.P.; Kaufmann, M.; Weber, S.; Irwin, A.; Goos, C.; John, U.; Misselwitz, J.; Klaus, G.; Kuwertz-Bröking, E.; Fehrenbach, H.; Wingen, A.; Güran, T.; Hoenderop, J.; Bindels, R.; Prosser, D.; Jones, G.; Konrad, M. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med., 2011, 365, 410-421.
3. Holick, M. Resurrection of vitamin D deficiency and rickets. J. Clin. Invest., 2006, 116, 2062-2072.
4. Bischoff-Ferrari, H.; Willett, W.; Wong, J.; Stuck, A.; Staehelin, H.; Orav, J.; Thoma, A.; Kiel, D.; Henschkowski, J. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch. Int. Med., 2009, 169, 551-561.
5. Adami, S.; Giannini, S.; Bianchi, G.; Sinigalia, L. Di.; Munno, O.; Fiore, C.E.; Minisola, S.; Rossini, M. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos. Int., 2009, 20, 239-244.
6. Carmel, E.S.; Shieh, A.; Bang, H.; Bockman, R.S. The 25(OH)D level needed to maintain a favourable bisphosphonate response is >33 ng/mL. Osteoporos. Int., 2012, Jan 12 [Epub ahead of print].
7. Bischoff-Ferrari, H.; Dawson-Hughes, B.; Staehelin, H.B.; Orav, J.; Stuck, A.; Theiler, R.; Wong, J.; Egli, A.; Kiel, D.; Henschkowski, J. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ, 2009, 339, b3692.
8. Hewison, M. Antibacterial effects of vitamin D. Nat. Rev. Endocrinol., 2011, 7, 337-345.
9. Boonstra, A.; Barrat, F.; Crain, C.; Heath, V.; Savelkoul, H.; O'Garra, A. 1,25-dihydroxyvitamin D3 has a direct effect on naïve CD4+T cells to enhance the development of Th2 cells. J. Immunol., 2001, 167, 4974-4980.
10. Pilz, S.; Tomaschitz, A.; Ritz, E. Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol., 2009, 6, 621-630.
11. Ma, Y.; Zhang, P.; Wang, F.; Yang, J.; Liu, Z.; Qin, H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J. Clin. Oncol., 2011, 29, 3775-3782.
12. Bodnar, L.; Catov, J.; Simhan, H.; Holick, M.; Powers, R.; Roberts, J. Maternal vitamin D deficiency increases the risk of preeclampsia. J. Clin. Endocrinol. Metab., 2007, 92, 3517-3522.
13. Zhang, C.; Qiu, C.; Hu, F.; David, R.; van Dam, R.; Bralley, A.; Williams, M. Maternal plasma 25-hydroxyvitamin D concentrations and the risk for gestational diabetes mellitus. PloS ONE, 2008, 3, e3753.
14. Brannon, P.; Picciano, M.F. Vitamin D in pregnancy and lactation in humans. Annu. Rev. Nutr., 2011, 31, 89-115.
15. Hollis, B.W.; Johnson, D.; Hulsey, T.C.; Ebeling, M.; Wagner, C. Vitamin D supplementation during pregnancy: double blind randomized clinical trial of safety and effectiveness. J. Bone Miner. Res., 2011, 26, 2341-2357
16. Holick, M.; Binkley, N.; Bischoff-Ferrari, H.; Gordon, C.; Hanley, D.; Heaney, R.; Murad, H.; Weaver, C. Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab., 2011, 96, 1911-1930.
17. Ross, C.; Manson, J.E.; Abrams, S.; Aloia, J.; Brannon, P.; Clinton, S.; Durazo-Arvizu, R.; Gallagher, J.C.; Gallo, R.; Jone, G.; Kovacs, C.; Mayne, S.; Rosen, C.; Shapes, S. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab., 2011; 96, 53-58.
18. Munger, K.; Levin, L.; Hollis, B.; Howard, N.; Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 2006, 296, 2832-2838.
19. Giovanucci, E. Epidemiological evidence for vitamin D and colorectal cancer. J. Bone Miner. Res., 2007, 22, V81-V85.
20. Engel, P.; Fagherazzi, G.; Boutten, A.; Dupré, T.; Mesrine, S.; Boutron-Ruault, M.C.; Clavel-Chapelon, F. Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 2341-2350.
21. Leu, M.; Giovannucci, E. Vitamin D: epidemiology of cardiovascular risks and events. Best Pract. Res. Cl. En., 2011, 25, 633-646.
22. Adams, J.; Hewison, M. Update in vitamin D. J. Clin. Endocrinol. Metab., 2010, 95, 471-478.
23. Norman, A. Vitamin D nutrition is at a crossroads. Public Health Nutrition, 2011, 14, 750-751.
24. Dawson-Hughes, B.; Mithal, A.; Bonjour, J.P.; Boonen, S.; Burckardt, P.; Fuleihan, G.E.H.; Josse, R.G.; Lips, P.; Morales-Torres, J.; Yoshimura, N. IOF position statements: vitamin D recommendations for older adults. Osteoporos. Int., 2010, 21, 1151-1154.
25. Perez-Lopez, F.; Brincat, M.; Erel, T.; Erel, T.; Tremollieres, F.; Gambacciani, M.; Lambrinoudaki, I.; Moen, M.; Schenck-Gustafsson, K.; Vujovic, S.; Rozenberg, S.; Rees, M. EMAS position statement: vitamin D and postmenopausal health. Maturitas, 2012, 71, 194-198.
26. Vieth, R. Why the optimal requirement for vitamin D3 is probably much higher than what is officially recommended for adults. J. Steroid Biochem. Mol. Biol., 2004, 89, 575-579.
27. Bischoff-Ferrari, H.; Giovanucci, E.; Willett, W.; Dietrich, T.; Dawson-Hughes, B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple outcomes. Am. J. Clin. Nutr., 2006, 84, 18-28.
28. Dawson-Hughes, B.; Heaney, R.; Holick, M.; Lips, P.; Meunier, P.; Vieth, R. Estimates of optimal vitamin D status. Osteoporos. Int., 2005, 16, 713-716.
29. Hanley, D.; Cranney, A.; Jones, G.; Whiting, S.; Leslie, W.; Cole, D.; Atkinson, S.; Josse, R.; Feldman, S.; Kline, G.; Rosen, C. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ, 2010, 182, E610-E618.
30. Souberbielle, J.C.; Body, J.J.; Lappe, J.; Plebani, M.; Schoenfeld, Y.; Wang, T.; Bischoff-Ferrari, H.; Cavalier, H.; Ebeling, P.; Fardellone, P.; Gandini, S.; Gruson, D.; Guerin, A.; Heickendorff, L.; Hollis, B.; Ish-Shalom, S.; Jean, G.; von Landenberg, P.; Largura, A.; Olsson, T.; Pierrot-Deseilligny, C.; Pilz, S.; Tincani, A.; Valcour, A.; Zittermann, A. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmunity Reviews, 2010, 9, 709-715.
31. Priemel, M.; von Domarus, C.; Klatte, T.O.; Kessler, S.; Schlie, J.; Meier, S.; Proksch, N.; Pastor, F.; Netter, C.; Streichert, T.; Püschel, K.; Amling, M. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res., 2010, 25, 305-312.
32. Okazaki, R.; Sugimoto, T.; Kaji, H.; Fujii, Y.; Shiraki, M.; Inoue, D.; Endo, I.; Okano, T.; Hirota, T.; Kurahashi, I.; Matsumoto, T. Vitamin D insufficiency defined by serum 25-hydroxyvitamin D and parathyroid hormone before and after oral vitamin D3 supplementation load in Japanese patients. J. Bone Miner. Metab., 2011, 29, 103-110.
33. Chapuy, M.C.; Preziosi, P.; Maamer, M.; Arnaud, S.; Galan, P.; Hercberg, S.; Meunier, P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int., 1997, 7, 439-443.
34. Heaney, R.; Dowell, M.; Hale, C.; Bendich, A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J. Am. Coll. Nutr., 2003; 22: 142-146.
35. Mithal, A.; Wahl, D.A.; Bonjour, J.P.; Burckardt, P.; Dawson-Hughes, B.; Eisman, J.; Fuleihan, G.E.H.; Josse, R.; Lips, P.; Morales-Torres, J. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int., 2009, 11,1807-1820.
36. Hathcock, J.; Shao, A.; Vieth, R.; Heaney, R. Risk assessment for vitamin D. Am. J. Clin. Nutr., 2007, 85: 6-18.
37. Tuohimaa, P.; Tenkanen, L.; Ahonen, M.; Lumme, S.; Jellum, E.; Hallmans, G.; Stattin, P.; Harvei, S.; Hakulinen, T.; Luostarinen, T.; Dillner, J.; Lehtinen, M.; Hakama, M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer, 2004,108,104-108.
38. Stolzenberg-Solomon, R.Z.; Jacobs, E.J.; Arslan, A.A.; Qi, D.; Patel, A.V.; Helzlsouer, K.J.; Weinstein, S.J.; McCullough, M.L.; Purdue, M.P.; Shu, X.; Snyder, K.; Virtamo, J.; Wilkins, L.; Yu, K.; Zelenius-Jacquotte, A.; Zheng, W.; Albanes, D.; Cai, Q.; Harvey, C.; Hayes, R.; Clipp, S.; Horst, R.L.; Irish, L.; Koenig, K., Le Marchand, L.; Kolonel, L.N. Circulating 25-hydroxyviatmin D and risk of pancreatic cancer: cohort consortium vitamin D pooling project of rarer cancers. Am. J. Epidemiol., 2010, 172, 81-93.
39. Luxwolda, M.; Kuiperst, R.; Kema, I.; Dijck-Brouwer, J.; Muskiet, F. Traditionnally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/L. British Journal of Nutrition, 2012, Jan 23, 1-5 [Epub ahead of print]
40. Hollis, B.W. The determination of circulating 25-hydroxyvitamin D: no easy task. J. Clin. Endocrinol. Metab., 2004, 89, 3149-3151.
41. Lensmeyer, G.; Poquette, M.; Wiebe, D.; Binkley, N. The C3-epimer of 25-hydroxyvitamin D3 is present in adult serum. J. Clin. Endocrinol. Metab., 2012, 97, 163-168.
42. Elder, P.; Lewis, J.; King, R.; Florkowski, C. An anomalous result from gel tubes for vitamin D. Clinica Chimica Acta, 2009, 410, 95.
43. Carter, G.; Jones, J.C.; Berry, J.L. The anomalous behaviour of exogenous 25-hydroxyvitamin D in competitive binding assays. J. Steroid Biochem. Mol. Biol., 2007, 103, 480-482.
44. Cavalier, E.; Wallace, M.; Knox, S.; Mistretta, V.; Cormier, C.; Souberbielle, J.C. Serum vitamin D measurement may not reflect what you give to your patients. J. Bone Miner. Res., 2008, 23, 1864-1865.
45. Binkley, N.; Drezner, M.; Hollis, B.W. Laboratory reporting of 25-hydroxyvitamin D results: potential for clinical misinterpretation. Clin. Chem., 2006, 52, 2124-2125.
46. Hollis, B.W. Comparison of commercially available (125)I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin. Chem., 2000, 46, 1657-1661.
47. Stepman, H.; Vanderroost, A.; Van Uytfanghe, K.; Thienpont, L. Candidate reference measurement procedures for serum 25OHD3 and 25OHD2 by using isotope dilution liquid chromatographytandem mass spectrometry. Clin. Chem., 2011, 57, 441-448.
48. Heijboer, A.; Blankenstein, M.; Kema, I.; Buijs, M. Accuracy of 6 routine 25-hydroxyvitamin D assays; influence of vitamin D binding protein concentration. Clin. Chem., 2012, 58 in press.
49. Farrell, C.J.; Martin, S.; McWhinney, B.; Straub, I.; Williams, P.; Hermann, M. State-of-the-art vitamin assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin. Chem., 2012, 53 in press.
50. Taieb, J.; Mathian, B.; Millot, F.; Patricot, M.C.; Mathieu, E.; Queyrel, N.; Lacroix, I.; Somma-Delpero, C.; Boudou, P. Testosterone measured by 10 immunoassays and by isotopedilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin. Chem., 2003, 49, 1381-1395.
51. Boudou, P.; Taieb, J.; Mathian, B.; Badonnel, Y.; Lacroix, I.; Mathieu, E.; Millot, F.; Queyrel, N.; Somma-Delpero, C.; Patricot, M.C. Comparison of progesterone concentration determination by 12 non-isotopic immunoassays and gas chromatography/mass spectrometry in 99 human serum samples. J. Steroid Biochem. Mol. Biol., 2001, 78, 97-104.
52. Barake, M.; Daher, R.; Salti I, Cortas N, Al-Saar L, Habib R, El-Hajj-Fuleihan G. 25-hydroxyvitamin D assay variations and impact on clinical, decision making. J Clin Endocrinol metab, 2012; 97: 835-843.
53. Binkley, N.; Krueger, D.; Cowgill, C.S.; Plum, L.; Lake, E.; Hansen, K.E.; DeLuca, H.; Drezner, M. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J. Clin. Endocrinol. Metab., 2004, 89, 3152-3157.
54. Hyppönen, E.; Turner, S.; Cumberland, P.; Power, C.; Gibb, I. Serum 25-hydroxyvitamin D measurement in a large population survey with statistical harmonization of assay variation to an international standard. J. Clin. Endocrinol. Metab., 2007, 92, 4615-4622.
55. Cavalier, E.; Rozet, E.; Gadisseur, R.; Carlisi, A.; Monge, M.; Chapelle, J.P.; Hubert, P.; Souberbielle, J.C.; Delanaye, P. Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cutoffs. Osteoporos. Int., 2010, 21, 1047-1051.
56. Davidson, Z.; Walker, K.; Truby, H. Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J. Clin. Endocrinol. Metab., 2012, 97, 738-744.
57. KDIGO. Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int., 2009, 79, S1-S130.
58. Kandula, P.; Dobre, M.; Schold, J.D.; Schreiber, M.; Mehrotra, R.; Navaneethan, S. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin. J. Am. Soc. Nephrol., 2011, 6, 50-62.
59. Jean, G.; Souberbielle, J.C.; Chazot, C. Strategy for vitamin D supplementation. Monthly cholecalciferol administration in hemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol. Dial. Transplant., 2009, 24, 3799-3805.
60. Matias, P.J.; Jorge, C.; Ferreira, C.; Borges, C.; Aires, I.; Amaral, T.; Gil, C.; Cortez, J.; Ferreira, A. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimensions parameters. Clin. J. Am. Soc. Nephrol., 2010, 5, 905-911.
61. Courbebaisse, M.; Thervet, E.; Souberbielle, J.C.; Zuber, J.; Eladari, D.; Martinez, F.; Mamzer-Bruneel, M.F.; Urena, P.; Legendre, C.; Friedlander, G.; Prié, D. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int., 2009, 75, 646-651.
62. Pilz, S.; Iodice, S.; Zittermann, A.; Grant, W.; Gandini, S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis., 2011, 58, 374-382.
63. de Boer, I.H.; Katz, R.; Chonchol, M.; Sarnak, M.; Shlipak, M.; Siskovick, D.; Kestenbaum, B. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin. J. Am. Soc. Nephrol., 2011, 6, 2141-2149.
64. Kim, M.J.; Frankel, A.; Donaldson, M.; Darch, S.; Pusey, C.; Hill, P.; Mayr, M.; Tam, F. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin -aldosterone system inhibition. Kidney Int., 2011, 80, 851-860.
65. Grey, A.; Lucas, J.; Horne, A.; Gamble, G.; Davidson, J.; Reid, I. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab., 2005, 90, 2122-2126.
66. Souberbielle, J.C.; Maury, E.; Friedlander, G.; Cormier, C. Vitamin D and primary hyperparathyroidism (PHPT). J. Steroid. Biochem. Mol. Biol., 2010, 121, 199-203.
67. Eastell, R.; Arnold, A.; Brandi, M.L.; Brown, E.; D'Amour, P.; Hanley, D.; Rao, S.; Rubin, M.; Goltzman, D.; Silverberg, S.; Marx, S.; Peacock, M.; Mosekilde, L.; Bouillon, R.; Lewiecki, E. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab., 2009, 94, 340-350.
68. Lowe, H.; McMahon, D.J.; Rubin, M.; Bilezikian, J.; Silverberg, S. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab., 2007, 92, 3001-3005.
69. Heaney, R.P. Vitamin D in health and disease. Clin. J. Am. Soc. Nephrol., 2008, 3, 1535-1541.
70. Cashman, K.; Fitzgerald, A.; Kiely, M; Seamans, K. A systematic review and meta-regression analysis of the vitamin D intake-serum 25-hydroxyvitamin D relationship to inform European recommendations. Br. J. Nutr., 2011, 106, 1617-1627.
71. Gallagher, J.C.; Sai, A.; Templin III, T.; Smith, L. Dose response to vitamin D supplementation in postmenopausal women. A randomized trial. Ann. Intern. Med., 2012, 156, 425-437.
72. Toss, G.; Magnusson, P. Is a daily supplementation with 40 microgram vitamin D3 sufficient? A randomikzed trial. Eur. J. Nutr., 2011, [Epub ahead of print].
73. Diamond, T.; Wong, Y.K.; Golombick, T. Effect of oral cholecalciferol 2,000 versus 5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D deficiency. Osteoporos. Int., 2011, Epub ahead of print
74. van Groningen, L.; Opdenoordt, S.; van Sorge, A.; Telting, D.; Giesen, A.; de Boer, H. Choecalciferol loading dose guideline for vitamin D deficient adults. Eur. J. Endocrinol., 2010, 162, 805-11.
75. Holick, M.F. Vitamin D deficiency. N. Engl. J. Med., 2007, 357, 266-81.
76. Ish-Shalom, S.; Segal, E.; Salganik, T.; Raz, B.; Bromberg, I.; Vieth, R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J. Clin. Endocrinol. Metab., 2008, 93, 3430-3435.
77. Sanders, K.M.; Stuart, A.L.; Williamson, E.J.; Simpson, J.; Kotowicz, M.; Young, D.; Nicholson, G. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. J.A.M.A., 2010, 303, 1815-1822.
78. Armas, L.A.G.; Hollis, B.W.; Heaney, R.P. Vitamin D2 is much less effective than vitamin D3 in humans. J. Clin. Endocrinol. Metab., 2004, 89, 5387-5391.
79. Romagnoli, E.; Mascia, M.L.; Cipriani, C.; Fassino, V.; Mazzei, F.; D'Erasmo, E.; Carnevale, V.; Scillitani, A.; Minisola, S. Short and long term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamine D3) in the elderly. J. Clin. Endocrinol. Metab., 2008, 93, 3015-3020.
80. Holick, M.; Biancuzzo, R.M.; Chen, T.C.; Klein, E.; Young, A.; Bibuld, D.; Reitz, R.; Salameh, W.; Ameri, A.; Tannenbaum, A. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J. Clin. Endocrino.l Metab., 2008, 93, 677-681.
81. Heaney, R.; Recker, R.; Grote, J.; Horst, R.; Armas, L. Vitamin D3 is more potent than vitamin D2 in humans. J. Clin. Endocrinol. Metab., 2011, 96, E447-E452.